华东医药：爱拉赫国内市场正式上市工作推进顺利，将于2025年11月正式落地

Core Viewpoint - The company has successfully initiated the market entry of its product ELAHERE® (Somatuzumab Injection) under the "Hong Kong and Macau Drug and Medical Device Access" policy, with significant sales revenue projected for the upcoming years [1]. Group 1: Product Launch and Sales - The product ELAHERE® has achieved sales revenue exceeding 45 million yuan from January to September 2025 [1]. - The official market launch of ELAHERE® in the domestic market is progressing smoothly, with plans for a formal rollout in November 2025 [1].